文献速递区域麻醉与超声术前评估与围术期医学

美国下肢大关节置换术中脂质体布比卡因使用趋势:一项基于人群的研究

Trends of liposomal bupivacaine utilization in major lower extremity total joint arthroplasty in the USA: a population-based study.
PubMed 文献 · Reg Anesth Pain Med · 2024-02-05

该研究基于Premier医疗数据库,分析2012至2021年103,165例择期下肢大关节置换术成人患者,发现脂质体布比卡因使用率从2012年0.4%升至2015年22.8%,此后每年下降约1%-3%,2021年为15.7%;约60%医院曾使用该药。

要点

  • 脂质体布比卡因使用率在2015年达峰后逐年下降。
  • 医院层面启动使用率2014年达峰后下降,终止率上升。
  • 非教学医院及南部和西部医院更可能长期保留使用。

核心结论

  • 脂质体布比卡因使用在2015年左右达到峰值后,在患者和医院层面均呈下降趋势。

研究设计与样本

  • 基于Premier医疗数据库的回顾性人群研究,纳入2012至2021年103,165例择期下肢大关节置换术成人患者。

主要发现

  • 脂质体布比卡因使用率从2012年0.4%升至2015年22.8%,此后每年下降约1%-3%,2021年为15.7%。
  • 约60%医院曾使用脂质体布比卡因。
  • 医院层面启动使用率从2013年32.8%降至2021年4.3%,终止率从2014年1.4%升至2019年9.9%。
  • 非教学医院及南部和西部医院更可能长期保留使用(p=0.023和p=0.014)。

临床怎么用

  • 麻醉科医生应关注脂质体布比卡因使用下降趋势,结合证据评估其成本效益。

局限性

  • 研究为回顾性数据库分析,趋势与健康结局及支出的相关性需未来研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Liposomal bupivacaine has been marketed for the achievement of long-acting local or regional anesthesia after major lower extremity total joint arthroplasty. However, it is comparatively expensive and controversy remains regarding its ability to decrease healthcare costs. With mounting evidence suggesting non-superiority in efficacy, compared with plain bupivacaine, we sought to investigate trends in liposomal bupivacaine use and identify changes in practice. METHODS: We identified adult patients from the Premier Healthcare Database who underwent elective total joint arthroplasty between 2012 and 2021. Prevalence and trends of liposomal bupivacaine utilization were compared on the individual patient and hospital levels. Log-rank tests were performed to assess the influence of location, teaching status, or hospital size on time to hospital-level liposomal bupivacaine termination. RESULTS: Among 103,165 total joint arthroplasty cases, liposomal bupivacaine use increased between 2012 and 2015 (from 0.4% to 22.8%) and decreased by approximately 1%-3% annually thereafter (15.7% in 2021). Liposomal bupivacaine was ever used in approximately 60% of hospitals. Hospital-level initiation of liposomal bupivacaine use peaked in 2014 and decreased thereafter (from 32.8% in 2013 to 4.3% in 2021), while termination rates increased (from 1.4% in 2014 to 9.9% in 2019). Non-teaching hospitals and those located in the South and West regions were more likely to retain liposomal bupivacaine longer than teaching or Midwest/Northeast hospitals, respectively (p=0.023 and p=0.014). DISCUSSION: Liposomal bupivacaine use peaked around 2015 and has been declining thereafter on individual patient and hospital levels. How these trends correlate with health outcomes and expenditures would be a strategic target for future research.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Stundner O, Hoerner E, Zhong H, et al. Trends of liposomal bupivacaine utilization in major lower extremity total joint arthroplasty in the USA: a population-based study. Reg Anesth Pain Med. 2024. PMID: 37567594. doi:10.1136/rapm-2023-104784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。